Two Sigma Advisers
JANX icon

Two Sigma Advisers’s Janux Therapeutics JANX Stock Holding History

Two Sigma Advisers’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-104,100
Closed -$1.44M – 1083
2025
Q4 		$1.44M Buy
+104,100
New +$2.45M ﹤0.01% 1315
2024
Q3 		– Sell
-19,300
Closed -$808K – 2401
2024
Q2 		$808K Sell
19,300
-63,700
-77% -$2.99M ﹤0.01% 1660
2024
Q1 		$3.12M Buy
83,000
+59,400
+252% +$1.29M 0.01% 987
2023
Q4 		$253K Buy
+23,600
New +$204K ﹤0.01% 2164

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Advisers's JANX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 104,100 shares — an estimated $1.44M sold.

Two Sigma Advisers first reported a position in JANX in Q4 2023 and held it in 4 quarters. The position peaked at $3.12M in Q1 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 104,100 Janux Therapeutics shares in Q1 2026, an estimated $1.44M.
  • Two Sigma Advisers first reported a position in Janux Therapeutics in Q4 2023 and held it in 4 quarters.
  • Two Sigma Advisers's Janux Therapeutics position peaked at $3.12M in Q1 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.